Missouri Attorney General Catherine Hanaway has expanded her statewide investigation into manufacturers and businesses selling kratom and synthetic 7-OH products, issuing Civil Investigative Demands to nine retailers following "troubling reports that consumers may be exposed to unapproved, unsafe and deceptively marketed opioid-like drugs." The investigation, which began with six CIDs issued in late November, includes three Kansas City metro businesses and targets suspected violations of Missouri consumer protection laws.

Several companies received CIDs requiring disclosure of how products are made, labeled, and any communications regarding safety of suspected psychoactive substances.

"Our Office will not back down against businesses that choose to profit by selling powerful psychoactive compounds outside the law," Attorney General Hanaway stated. "Missourians have the right to know exactly what is in the products they consume, and they deserve honesty, not companies willing to put their health in jeopardy."

The 7-OH Controversy

The investigation focuses particularly on 7-hydroxymitragynine, or 7-OH, a compound found in very small amounts in natural kratom. About two years ago, American Shaman founder Vince Sanders learned how to extract 7-OH from kratom and produce it in concentrated, synthetic tablet form. The product's widespread availability and lack of regulation have skyrocketed demand while generating intense controversy.

Doctors, health departments, and addiction prevention advocates have criticized the product, often referring to it as "gas station heroin" for its opioid-like effects and addiction properties. Kansas City, Missouri's health department has reported at least one polysubstance death involving kratom and/or 7-OH, prompting Mayor Quinton Lucas to propose a blanket ban on selling all unregulated products.

Sanders and some users have defended the product as a safe harm reduction option for pain management and recovering addicts. "It's really a matter of properly using this product and using it the way that the label would indicate," Sanders said. "As long as you do that, you just don't see problems."

FDA Enforcement Action

The FDA recently seized more than 70,000 7-OH products from warehouses in Kansas City, escalating federal enforcement against synthetic kratom products. Sanders claims the agents lacked grounds for the seizure, asserting the FDA did not respond to American Shaman's warning letter response. He filed a motion to dismiss the case on December 11, challenging the agency's authority to take enforcement action without providing opportunity to address concerns raised in the warning letter.

The FDA seizure represents significant federal intervention in a market previously operating primarily under state and local oversight. Federal agencies historically have limited involvement in kratom regulation, making this enforcement action notable for its scope and the volume of products removed from commerce. The seizure demonstrates that even without formal scheduling or comprehensive regulatory framework, the FDA retains authority to act against products it determines pose public health risks.

Civil Investigative Demands and Compliance Requirements

Civil Investigative Demands represent powerful investigative tools enabling attorneys general to compel businesses to produce documents, answer interrogatories, and provide testimony regarding suspected violations of consumer protection laws. The Missouri CIDs require targeted businesses to disclose manufacturing processes, labeling practices, safety communications, and marketing materials related to kratom and 7-OH products.

These demands typically precede formal enforcement actions, providing attorneys general with information necessary to determine whether violations occurred and what remedies might be appropriate. Businesses receiving CIDs must respond comprehensively within specified timeframes, producing all requested documents and information. Failure to comply can result in court orders compelling compliance and potential contempt sanctions.

For businesses selling kratom or 7-OH products, CIDs create immediate compliance burdens requiring document collection, legal review, and strategic decisions about how to respond. Companies must evaluate whether their products, labeling, and marketing practices comply with applicable laws while considering whether voluntary changes might address investigative concerns before formal enforcement actions commence.

Implications for Kratom Industry

The Missouri investigation reflects growing state-level enforcement against kratom and synthetic derivatives even in jurisdictions without comprehensive regulatory frameworks. Attorneys general nationwide possess broad authority to investigate and prosecute deceptive trade practices, enabling enforcement against products marketed with unsubstantiated claims or sold without adequate safety disclosures regardless of whether specific kratom regulations exist.

The focus on "deceptively marketed opioid-like drugs" suggests that enforcement targets extend beyond product composition to marketing claims and consumer disclosures. Businesses selling kratom products must ensure that marketing materials don't make unsubstantiated health claims, product labeling provides adequate safety information, products are accurately described without misleading "all natural" claims for synthetic variants, and consumers receive clear information about addiction potential and appropriate usage.

Attorney General Hanaway's statement that "Missourians have the right to know exactly what is in the products they consume" emphasizes transparency as a core enforcement priority. Even where products aren't explicitly prohibited, deceptive marketing or inadequate disclosure creates legal vulnerability under consumer protection statutes that exist in every state.

Building Defensible Compliance Programs

The expanded Missouri investigation underscores the importance of proactive compliance programs for businesses selling kratom or other controversial botanical products. Manufacturers and retailers should implement comprehensive quality management systems ensuring product composition matches labeling, testing protocols verify absence of undisclosed adulterants, marketing claims are substantiated by scientific evidence, and safety information is prominently disclosed to consumers.

Documentation becomes critical when facing investigative demands. Businesses must maintain records demonstrating manufacturing controls, testing results, label approval processes, and marketing review procedures. When attorneys general issue Civil Investigative Demands, comprehensive documentation enables businesses to respond efficiently while demonstrating good faith compliance efforts even if specific practices require modification.

Contact Qredible today to learn how our quality management solutions help kratom and botanical supplement businesses implement comprehensive documentation systems, maintain defensible compliance programs, and build the transparency infrastructure necessary to withstand regulatory scrutiny in an increasingly enforcement-focused environment.